Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 vs QL1604 in LS-SCLC Consolidation
NCT06789796Phase 3Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Feb 2025
- Primary completion
- Mar 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of QL1706 in small cell lung cancer (SCLC) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Progression-free survival at 2 years and Overall survival at 5 years. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06789796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06789796.